Lysogene, a developer of treatments for severe genetic pathologies with central nervous system involvement, has raised €16.5 million ($22.5 million) in Series A financing. Returning investor Sofinnova Partners co-led the round with new investors Bpifrance and Novo A/S. Rafaèle Tordjman of Sofinnova and Henrijette Richter of Novo A/S will join the company's Board as part of the financing.
Lysogene was founded in 2009 and specializes in intracerebral gene therapy aimed at treating neurodegenerative diseases. Its lead product, rAAVrh10, is for treatment of Sanfilippo, a neurodegenerative lysosomal storage disorder.